Skip to main content

Table 3 Baseline features of the participants

From: Efficacy and safety of adding rivaroxaban to the anti-platelet regimen in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

Trials Age (years) Males (%) HT (%) Ds (%) DM (%) Cs (%)
  R/placebo R/placebo R/placebo R/placebo R/placebo R/placebo
ATLAS-ACS 2 TIMI 51 61.9/61.5 74.6/75.0 67.4/67.5 48.7/48.2 32.1/31.8
GEMINI-ACS-1 62.0/63.0 75.0/75.0 71.0/75.0 56.0/56.0 29.0/30.0 32.0/34.0
COMPASS 68.3/68.2 67.5/68.2 75.5/75.4 37.7/38.1 3.80/3.70
ATLAS-ACS-TIMI 46 57.2/57.8 77.6/76.3 57.4/56.9 44.4/43.6 19.4/19.1 61.9/62.6
  1. R rivaroxaban group, HT hypertension, Ds dyslipidemia, DM diabetes mellitus, Cs current smoker